30 results
8-K
EX-99.1
FULC
Fulcrum Therapeutics Inc
27 Feb 24
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results
7:01am
of mobility and independence, and chronic pain. FSHD is one of the most common forms of muscular dystrophy and has an estimated patient population
8-K
EX-99.1
FULC
Fulcrum Therapeutics Inc
7 Nov 23
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results
7:02am
, loss of upper limb function, loss of mobility and independence, and chronic pain. FSHD is one of the most common forms of muscular dystrophy and has
8-K
EX-99.1
FULC
Fulcrum Therapeutics Inc
22 Aug 23
Regulation FD Disclosure
7:01am
Measures of Severity VOC ≥2 over 12 months Chronic kidney ≥2 other ≥4 over 12 disease or and at least one measures of months or ≥2 other measure … pulmonary artery pressure 25 mm Hg ▪ SCD-related chronic kidney disease (CKD) defined by at least one of the following criteria measured on 2
8-K
EX-99.1
8w9vuhnx28z7fs4
3 Aug 23
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results
7:05am
8-K
EX-99.1
crx7 b5lhabluv
15 May 23
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results
7:06am
8-K
g9fsj
15 May 23
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results
7:06am
424B5
yotpgkm4r 77r3m6w
16 Aug 22
Prospectus supplement for primary offering
5:55pm
424B5
i44o8i7e2p3h9q
15 Aug 22
Prospectus supplement for primary offering
6:14pm
8-K
EX-99.1
ikx4z
3 Mar 22
Fulcrum Therapeutics® Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results
7:03am
8-K
EX-99.1
igbr03
10 Jan 22
Fulcrum Therapeutics® Announces Upcoming Milestones to Support Its Mission of Treating the Root Cause of Rare Genetic Diseases
7:07am
424B5
g6s80y63ejtphdo31j3
12 Aug 21
Prospectus supplement for primary offering
4:38pm
424B5
qk6jrhxzq 6pnmm04kj
11 Aug 21
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
0b54l
10 Jun 20
Entry into a Material Definitive Agreement
4:15pm